Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2024-11-14 09:09 am Sale | 13G | Abivax S.A. ABVX | Deep Track Capital LP | 3,579,209 5.080% | -718,229 (-16.71%) | View |
| 2024-04-19 7:09 pm Purchase | 13G | Abivax S.A. ABVX | TCG Crossover GP I LLC | 6,056,596 9.600% | 6,056,596 (New Position) | View |
| 2024-02-14 8:25 pm Purchase | 13G | Abivax S.A. ABVX | Venrock Healthcare Capital Partners III L.P. | 3,611,570 5.700% | 298,570 (+9.01%) | View |
| 2023-11-22 4:16 pm Purchase | 13G | Abivax S.A. ABVX | Venrock Healthcare Capital Partners III L.P. | 3,313,000 5.300% | 3,313,000 (New Position) | View |
| 2023-10-30 4:13 pm Purchase | 13G | Abivax S.A. ABVX | Deep Track Capital LP | 4,297,438 6.140% | 4,297,438 (New Position) | View |
| 2023-10-30 1:42 pm Purchase | 13D | Abivax S.A. ABVX | Sofinnova Crossover I | 6,948,613 8.000% | 6,948,613 (New Position) | View |